Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019
In the latest years, antineoplastic immunotherapy revolutionised the therapeutic landscape in oncology. First shown to be effective in melanoma and non-small cell lung carcinoma, immune checkpoint inhibitors are now being tested for the treatment of hepatocellular carcinoma (HCC). Preliminary results have been particularly promising. As a consequence, an increasing number of clinical trials are underway. The role of the immune system in carcinogenesis (with particular reference to tumour escape immune mechanisms), as well as the current immunotherapy trials for HCC in its different clinical scenarios, are the subject of this review.
Source: Digestive and Liver Disease - Category: Gastroenterology Authors: Francesco Tovoli, Andrea Casadei-Gardini, Francesca Benevento, Fabio Piscaglia Tags: Review article Source Type: research
More News: Cancer & Oncology | Carcinoma | Clinical Trials | Gastroenterology | Hepatocellular Carcinoma | Immunotherapy | Liver | Liver Cancer | Liver Disease | Melanoma | Non-Small Cell Lung Cancer | Skin Cancer | Study | Urology & Nephrology